(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M
10x Genomics (TXG) updated its outlook for 2026 revenue to a range of $610M to $630M, compared with a FactSet estimate of $613.7M. The article also notes that the company’s Q2 results turned to a loss and revenue declined.
How this was made
The 30-second read
Why it matters
A new 2026 revenue range updates the estimate trajectory and can drive revisions to FY2026 revenue forecasts and related valuation multiples.
Market read
Traders can use the guidance range versus consensus to judge whether TXG’s forward expectations are being reset higher or held steady.
What to watch
The article does not include prior guidance, product/market drivers, or margin assumptions, which are often what determine whether revenue guidance is bullish or merely neutral.
Background
The text references a prior item that “10x Genomics Q2 swings to loss, revenue falls,” framing this guidance as a forward-looking offset.
Ticker impact
10x Genomics guides 2026 revenue to $610M-$630M, versus FactSet est of $613.7M, setting a fresh consensus anchor.
Near-term reaction likely depends on whether the midpoint ($620M) is viewed as credible versus prior expectations; range is close to consensus.
The article provides a specific guidance range and a consensus comparison, but lacks prior guidance, segment detail, or margin/FCF implications.
Market effects
Guidance from a key genomics tools name can influence sentiment around biotech research-instrument spending expectations.
Primarily US small/mid-cap growth sentiment, with limited direct regional spillover implied by the text.
Modest, as the disclosure is company-specific and no broader regulatory or macro driver is mentioned.
Counterpoint
Because the midpoint is close to the FactSet estimate, the guidance may not change earnings power materially, limiting sustained upside.
Key entities
- public_company10x Genomics
Provides 2026 revenue guidance of $610M-$630M and compares it to a FactSet consensus of $613.7M.
